Search results for "Liver Fibrosi"

showing 10 items of 113 documents

Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease

2012

Background: Metabolic factors have been associated with liver damage in patients with non-alcoholic fatty liver disease (NAFLD). Aims To test a new marker of adipose dysfunction, the visceral adiposity index (VAI), in NAFLD patients to assess whether or not it is associated with host factors, and to investigate a potential correlation with histological findings. Methods One hundred and forty-two consecutive NAFLD patients were evaluated by liver biopsy, and clinical and metabolic measurements, including insulin resistance with the homeostasis model assessment (HOMA), and VAI by using waist circumference, body mass index, triglycerides and HDL. Serum levels of TNFα, IL-6, adiponectin and lep…

Settore MED/12 - Gastroenterologiavisceral adiposity index nafld liver fibrosis liver biopsySettore MED/08 - Anatomia PatologicaSettore MED/13 - Endocrinologia
researchProduct

Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) …

2017

Background HCV GT4 accounts for up to 20% of HCV infections worldwide. Simeprevir, given for 12 weeks as part of a 24- or 48-week combination regimen with PR is approved for the treatment of chronic HCV GT4 infection. Primary study objectives were assessment of efficacy and safety of simeprevir plus PR in treatment-naïve patients with HCV GT4 treated for 12 weeks. Primary efficacy outcome was sustained virologic response 12 weeks post-treatment (SVR12). Additional objectives included investigation of potential associations of rapid virologic response and baseline factors with SVR12. Methods This multicentre, open-label, single-arm study (NCT01846832) evaluated efficacy and safety of simepre…

SimeprevirMalePsychologie appliquéeFetge - MalaltiesHepacivirusGastroenterologyPolyethylene GlycolPolyethylene Glycols0302 clinical medicinelcsh:Science61 - MedicinaLiver DiseasesSciences bio-médicales et agricolesCirrhosisInterferonLiver Fibrosis030211 gastroenterology & hepatologyDrug Therapy CombinationViral loadBiologieHumanmedicine.medical_specialtyCiències multidisciplinàriesGenotypeSaudi ArabiaAlpha interferon:Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]Gastroenterology and HepatologyMicrobiologyAntiviral Agents03 medical and health sciencesHumansAgedMedicine and health sciencesHepaciviruFlavivirusesInterleukinslcsh:ROrganismsInterleukinmedicine.diseaseRegimen:Digestive System Diseases::Liver Diseases [DISEASES]chemistryImmunologylcsh:QMedicaments - AdministracióDevelopmental BiologyRNA viruseslcsh:Medicinemedicine.disease_cause:Other subheadings::Other subheadings::/drug therapy [Other subheadings]Geographical Locationschemistry.chemical_compoundSimeprevirHospital Universitari Vall d’Hebron030212 general & internal medicinePathology and laboratory medicineMultidisciplinaryHepatitis C virusHepatitis CRecombinant ProteinMedical microbiologyMiddle AgedViral LoadHepatitis CRecombinant Proteins:enfermedades del sistema digestivo::enfermedades hepáticas [ENFERMEDADES]EuropeResearch DesignVirusesFemalePathogensResearch ArticleAdultAsiaAdolescentClinical Research DesignHepatitis C virusResearch and Analysis MethodsYoung AdultInternal medicineRibavirinmedicineddc:610Rapid Virologic ResponseAntiviral AgentBiology and life sciencesbusiness.industryRibavirinViral pathogensInterferon-alphaFibrosisHepatitis virusesMicrobial pathogensPeople and PlacesAdverse EventsInterferonsbusinessPLoS ONE
researchProduct

IL28B and PNPLA3 Polymorphisms Affect Histological Liver Damage in Patients with Non-alcoholic Fatty Liver Disease.

2012

Background & Aims: Genetic background may affect liver damage in patients with non-alcoholic fatty liver disease (NAFLD). The main outcomes of the study were to assess whether IL28B rs12979860 and rs8099917 polymorphisms, together with PNPLA3 rs738409 C>G polymorphism, are associated with lobular inflammation and fibrosis, in NAFLD patients. Methods: One hundred sixty consecutive NAFLD patients were assessed by liver biopsy (Kleiner score); anthropometric, and biochemical and metabolic features were included. IL28B rs12979860 C>T, IL28B rs8099917 G>C, and PNPLA3 rs738409 C>G single nucleotide polymorphisms were tested. Results: Seventy-four (46.2%) patients had IL28B rs12979860 CC polymorph…

Univariate analysismedicine.medical_specialtyPathologySettore MED/12 - GastroenterologiaHepatologymedicine.diagnostic_testFatty liverliver fibrosiSingle-nucleotide polymorphismBiologySettore MED/08 - Anatomia Patologicamedicine.diseaseGastroenterologynonalcoholic fatty liver IL28B PNPLA3 PolymorphismsInterleukin 28BFibrosisInternal medicineLiver biopsyGenotypemedicinenafld liver biopsyHyperuricemia
researchProduct

Creatine consumption and liver disease manifestations in individuals aged 12 years and over

2022

Despite the overwhelming safety evidence concerning creatine intake in various settings, there is still incomplete information whether dietary creatine affects liver health at the population level. The main aim of this cross-sectional population-based study was to evaluate the association between creatine intake through regular diet and liver disease manifestations, including liver fibrosis and hepatic steatosis, among individuals aged 12 years and over, using open-source data from the 2017–2018 U.S. National Health and Nutrition Examination Survey (NHANES). A total of 9254 male and female participants of all ages were included in the 2017–2018 NHANES round. We extracted data from the total…

VDP::Medisinske Fag: 700::Helsefag: 800::Ernæring: 811VDP::Medisinske Fag: 700::Helsefag: 800Food Scienceliver fibrosis ; diet ; blood liver panel ; hepatic steatosis ; NHANES ; creatine
researchProduct

High performance of intravoxel incoherent motion diffusion MRI in detecting viral hepatitis-b induced liver fibrosis.

2019

Background: Recently a small cohort study demonstrated that intravoxel incoherent motion (IVIM) diffusion MRI can detect early stage liver fibrosis. Using modified IVIM data acquisition parameters, the current study aims to confirm this finding. Methods: Twenty-six healthy volunteers, three patients of chronic viral hepatitis-b but without fibrosis and one mild liver steatosis subject, and 12 viral hepatitis-b patients with fibrosis (stage 1–2=7, stage 3–4=5) were included in this study. With a 1.5-T MR scanner and respiration-gating, IVIM diffusion imaging was acquired using a single-shot echo-planar sequence with a b -value series of 2, 0, 1, 15, 20, 30, 45, 50, 60, 80, 100, 200, 300, 600…

business.industryLiver fibrosisViral hepatitis bGeneral Medicinemedicine.disease030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineFibrosismedicine030211 gastroenterology & hepatologyOriginal ArticleStage (cooking)Nuclear medicinebusinessViral hepatitisPerfusionIntravoxel incoherent motionDiffusion MRIAnnals of translational medicine
researchProduct

Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) - lack of interference by iron deposition.

2009

The correlation between liver stiffness, measured by transient elastography, liver fibrosis, using the histological METAVIR score, and iron overload, measured by atomic absorption spectrometry was evaluated in 56 homozygous-b-thalassaemics. Liver stiffness increased proportionally to liver fibrosis staging (r = 0Æ70; P > 0Æ001) independently of liver iron concentration (r = 0Æ01; P = 0Æ932). The area under the receiver-operating characteristic curve for prediction of cirrhosis was 0Æ997 (95% confidence interval [CI]: 0Æ925–1Æ000) with cut-off of 13 kPa with 100% sensitivity (95% CI: 69Æ0–100Æ0) and 95% specificity (95% CI: 84Æ2–99Æ3). Transient elastography is a reliable non-invasive tool f…

cirrhosis liver fibrosis liver iron concentration thalassaemia transient elastography
researchProduct

SEAL program – Early detection of liver fibrosis and cirrhosis by screening of the general population

2021

education.field_of_studymedicine.medical_specialtyCirrhosisbusiness.industryLiver fibrosisPopulationEarly detectionmedicine.diseaseSeal (mechanical)GastroenterologyInternal medicinemedicineeducationbusinessZeitschrift für Gastroenterologie
researchProduct

Cuantificación de la fibrosis hepática mediante biomarcadores de imagen

2018

There is a need for early identification of patients with chronic liver diseases due to their increasing prevalence and morbidity-mortality. The degree of liver fibrosis determines the prognosis and therapeutic options in this population. Liver biopsy represents the reference standard for fibrosis staging. However, given its limitations and complications, different non-invasive methods have been developed recently for the in vivo quantification of fibrosis. Due to their precision and reliability, biomarkers' measurements derived from Ultrasound and Magnetic Resonance stand out. This article reviews the different acquisition techniques and image processing methods currently used in the evalu…

education.field_of_studymedicine.medical_specialtymedicine.diagnostic_testbusiness.industryLiver fibrosisPopulationMagnetic resonance imagingContext (language use)medicine.disease030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineFibrosisLiver biopsyClinical valuemedicine030211 gastroenterology & hepatologyRadiology Nuclear Medicine and imagingeducationIntensive care medicinebusinessReference standardsRadiología
researchProduct

Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index.

2011

Background Liver stiffness measurement (LSM) using transient elastography (TE) is used to stage fibrosis in patients with liver disease, diagnostic reliability and the factors affecting its performance in patients with non-alcoholic fatty liver disease (NAFLD) are incompletely understood. Aim To assess LSM. Methods Consecutive NAFLD patients (n = 169), assessed by liver biopsy (Kleiner score), anthropometrical, biochemical and metabolic features, underwent LSM using TE with standard M probe. Results Liver stiffness measurement was not reliable in 23 patients (14%) due to obesity. Among patients with a reliable TE, a LSM value >7.25 kPa was the best cut-off for predicting significant fibrosi…

fibroscan liver fibrosis liver biopsy nafld liver stiffness measurement
researchProduct

Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe

2018

All-oral direct-acting antiviral drugs (DAAs) for hepatitis C virus, which have response rates of 95% or more, represent a major clinical advance. However, the high list price of DAAs has led many governments to restrict their reimbursement. We reviewed the availability of, and national criteria for, interferon-free DAA reimbursement among countries in the European Union and European Economic Area, and Switzerland. Reimbursement documentation was reviewed between Nov 18, 2016, and Aug 1, 2017. Primary outcomes were fibrosis stage, drug or alcohol use, prescriber type, and HIV co-infection restrictions. Among the 35 European countries and jurisdictions included, the most commonly reimbursed …

hepatitis C virusHIV Infectionschemistry.chemical_compound0302 clinical medicineAntiviral Agents/economicsHIV-HCV co-infection030212 general & internal medicineReimbursementliver fibrosismedia_commonDasabuvirCoinfectionHealth PolicyGastroenterologyHepatitis C3. Good healthEuropeHepatitis C Chronic/complicationsInsurance Health Reimbursement030211 gastroenterology & hepatologySwitzerlandmedicine.drugmedicine.medical_specialtyHIV Infections/complicationsAntiviral AgentsDrug Costs03 medical and health scienceshepatitis C treatmentmedicineHumansmedia_common.cataloged_instanceEuropean UnionEuropean unionPWIDIntensive care medicineHepatitisdirect-acting antiviralHepatologybusiness.industryHepatitis C Chronicalcohol usemedicine.diseasereimbursementVirologyOmbitasvirchemistryParitaprevirRitonavirbusinesstreatment restrictionsThe Lancet Gastroenterology & Hepatology
researchProduct